These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 17508002)

  • 1. Viewpoint: What is the role of allogeneic haematopoietic cell transplantation in the era of reduced-intensity conditioning--is there still an upper age limit? A focus on myeloid neoplasia.
    Finke J; Nagler A
    Leukemia; 2007 Jul; 21(7):1357-62. PubMed ID: 17508002
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Progress of research on allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning regimen for treatment of myelodysplastic syndrome - review].
    Zhang Z; Li X
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Aug; 16(4):969-74. PubMed ID: 18718102
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
    Warlick ED; Cioc A; Defor T; Dolan M; Weisdorf D
    Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduced intensity conditioning (RIC) haematopoietic cell transplants in elderly patients with AML.
    Niederwieser D; Lange T; Cross M; Basara N; Al-Ali H
    Best Pract Res Clin Haematol; 2006; 19(4):825-38. PubMed ID: 16997186
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation with fludarabine and melphalan is associated with durable disease control in myelodysplastic syndrome.
    Nakamura R; Rodriguez R; Palmer J; Stein A; Naing A; Tsai N; Chang K; Slovak ML; Bhatia R; Spielberger R; Kogut N; Pullarkat V; Kirschbaum M; Forman SJ; O'Donnell MR
    Bone Marrow Transplant; 2007 Nov; 40(9):843-50. PubMed ID: 17724447
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of pre-transplant serum ferritin on outcomes of patients with myelodysplastic syndromes or secondary acute myeloid leukaemia receiving reduced intensity conditioning allogeneic haematopoietic stem cell transplantation.
    Lim ZY; Fiaccadori V; Gandhi S; Hayden J; Kenyon M; Ireland R; Marsh J; Ho AY; Mufti GJ; Pagliuca A
    Leuk Res; 2010 Jun; 34(6):723-7. PubMed ID: 19944463
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: the role of dose intensity.
    Shimoni A; Hardan I; Shem-Tov N; Yeshurun M; Yerushalmi R; Avigdor A; Ben-Bassat I; Nagler A
    Leukemia; 2006 Feb; 20(2):322-8. PubMed ID: 16307018
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Allogeneic hematopoietic stem cell transplantation (HSCT) after reduced intensity conditioning.
    Servais S; Baron F; Beguin Y
    Transfus Apher Sci; 2011 Apr; 44(2):205-10. PubMed ID: 21345734
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Favourable outcome for patients with myeloid disorders treated with fludarabine-melphalan reduced-intensity conditioning and allogeneic bone marrow stem cell transplantation without the use of T-lymphocyte-depleting antibodies.
    Malladi RK; Peniket AJ; Norton AE; Campbell AJ; Collins GP; Samol J; Eagleton H; Miller E; Morgenstern G; Jones J; Keen-Mcguire A; Barnardo M; Littlewood TJ
    Eur J Haematol; 2004 Aug; 73(2):85-92. PubMed ID: 15245506
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome.
    Schmid C; Schleuning M; Ledderose G; Tischer J; Kolb HJ
    J Clin Oncol; 2005 Aug; 23(24):5675-87. PubMed ID: 16110027
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A prospective multicenter trial of peripheral blood stem cell sibling allografts for acute myeloid leukemia in first complete remission using fludarabine-cyclophosphamide reduced intensity conditioning.
    Grigg AP; Gibson J; Bardy PG; Reynolds J; Shuttleworth P; Koelmeyer RL; Szer J; Roberts AW; To LB; Kennedy G; Bradstock KF
    Biol Blood Marrow Transplant; 2007 May; 13(5):560-7. PubMed ID: 17448915
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Autologous and allogeneic stem cell transplantation for myelodysplastic syndrome.
    de Witte T; Oosterveld M; Muus P
    Blood Rev; 2007 Jan; 21(1):49-59. PubMed ID: 16822600
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Upfront allogeneic blood stem cell transplantation for patients with high-risk myelodysplastic syndrome or secondary acute myeloid leukemia using a FLAMSA-based high-dose sequential conditioning regimen.
    Saure C; Schroeder T; Zohren F; Groten A; Bruns I; Czibere A; Galonska L; Kondakci M; Weigelt C; Fenk R; Germing U; Haas R; Kobbe G
    Biol Blood Marrow Transplant; 2012 Mar; 18(3):466-72. PubMed ID: 21963618
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Can reduced-intensity allogeneic transplantation cure older adults with AML?
    Storb R
    Best Pract Res Clin Haematol; 2007 Mar; 20(1):85-90. PubMed ID: 17336258
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of HCT-comorbidity index, age and disease status at transplantation in predicting survival and non-relapse mortality in patients with myelodysplasia and leukemia undergoing reduced-intensity-conditioning hemopoeitic progenitor cell transplantation.
    Bokhari SW; Watson L; Nagra S; Cook M; Byrne JL; Craddock C; Russell NH
    Bone Marrow Transplant; 2012 Apr; 47(4):528-34. PubMed ID: 21743502
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.
    Valcárcel D; Martino R; Caballero D; Martin J; Ferra C; Nieto JB; Sampol A; Bernal MT; Piñana JL; Vazquez L; Ribera JM; Besalduch J; Moraleda JM; Carrera D; Brunet MS; Perez-Simón JA; Sierra J
    J Clin Oncol; 2008 Feb; 26(4):577-84. PubMed ID: 18086801
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT).
    Aoudjhane M; Labopin M; Gorin NC; Shimoni A; Ruutu T; Kolb HJ; Frassoni F; Boiron JM; Yin JL; Finke J; Shouten H; Blaise D; Falda M; Fauser AA; Esteve J; Polge E; Slavin S; Niederwieser D; Nagler A; Rocha V;
    Leukemia; 2005 Dec; 19(12):2304-12. PubMed ID: 16193083
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of intensity of conditioning therapy in patients aged 40-60 years with AML/myelodysplastic syndrome undergoing allogeneic transplantation.
    Khabori MA; El-Emary M; Xu W; Guyatt G; Galal A; Kuruvilla J; Lipton J; Messner H; Gupta V
    Bone Marrow Transplant; 2011 Apr; 46(4):516-22. PubMed ID: 20622907
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Mini-transplant for acute myeloblastic leukemia and myelodysplastic syndrome].
    Kanda Y
    Nihon Rinsho; 2003 Sep; 61(9):1565-72. PubMed ID: 14515725
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.